8 research outputs found

    Adaptación del proyecto curricular en un centro de Educación Especial : proyecto de formación de centros

    No full text
    Proyecto curricular que pretende adaptar el currículo oficial a las características de los alumnos del centro, de forma que se preste atención a la diversidad del alumnado. Se tratarán, concretamente, las necesidades educativas especiales, en cuanto a ritmos de aprendizaje y capacidades. Esta adaptación curricular consiste en analizar los objetivos de las áreas y bloques de contenidos de las etapas de Educación Infantil, Primaria y Secundaria, proponer estrategias metodológicas, y elaborar criterios de evaluación. El currículo se ha organizado por etapas educativas: Infantil, Básica y de transición a la vida adulta. Para cada una de ellas se han propuesto las siguientes orientaciones didácticas: Metodología y Organización, Enseñanzas Transversales, y Evaluación de los alumnos y del contexto.MadridES

    PRACTICAL CLASSES IN THE ANIMAL CARE SPECIALTY OF THE LICEO UNIVERSITY TRAINING DIPLOMA: CREATION, USE AND EVALUATION OF COGNITIVELY ACCESSIBLE MATERIALS FOR YOUNG PEOPLE WITH INTELLECTUAL DISABILITIES

    No full text
    Memoria final del Proyecto Innova-Docencia nº 164, titulado "Elaboración y desarrollo de materiales accesibles para la formación de jóvenes con discapacidad intelectual en la Atención y Cuidado de Animales, mediante la intervención en el Proyecto Liceo". Contiene información sobre la creación de materiales y de un repositorio de los mismos disponibles en la Facultad de Veterinaria de la Universidad Complutense de Madrid y sobre la difusión realizada de los resultados obtenidos. También contiene información sobre la sensibilización sobre discapacidad intelectual realizada en la comunidad educativa complutense y en entornos laborales relacionados con el cuidado de animales y sobre la información recibida por los componentes del equipo para poder realizar esta actividad docente con jóvenes con discapacidad intelectual.Depto. de Farmacología y ToxicologíaFac. de VeterinariaFALSEsubmitte

    Estableciendo "puentes" entre la Universidad y el tejido social madrileño : cómo los estudiantes de la Asignatura Ciudad y Urbanismo pueden colaborar en la búsqueda de soluciones urbanísticas a históricas reclamaciones vecinales en el entorno de Puente de Vallecas

    Full text link
    Publicación de los trabajos elaborados por los estudiantes del curso 2022/23 de la asignatura Ciudad y Urbanismo (35001304) de la Escuela Técnica Superior de Arquitectura de la Universidad Politécnica de Madrid en el marco de un proyecto de Aprendizaje-Servicio y reflexiones sobre el proceso tanto de los agentes sociales que formaron parte del mismo, como de los profesores que ha participado en la docencia

    Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    Get PDF
    Altres ajuts: Alliance Bristol-Myers Squibb/Pfizer.Background: This study assessed the sociodemographic, functional, and clinical determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation (NVAF) attended in the internal medicine setting. Methods: A multicenter, cross-sectional study was conducted in NVAF patients who attended internal medicine departments for either a routine visit (outpatients) or hospitalization (inpatients). Results: A total of 961 patients were evaluated. Their antithrombotic management included: no treatment (4.7%), vitamin K antagonists (VKAs) (59.6%), direct oral anticoagulants (DOACs) (21.6%), antiplatelets (6.6%), and antiplatelets plus anticoagulants (7.5%). Permanent NVAF and congestive heart failure were associated with preferential use of oral anticoagulation over antiplatelets, while intermediate-to high-mortality risk according to the PROFUND index was associated with a higher likelihood of using antiplatelet therapy instead of oral anticoagulation. Longer disease duration and institutionalization were identified as determinants of VKA use over DOACs. Female gender, higher education, and having suffered a stroke determined a preferential use of DOACs. Conclusions: This real-world study showed that most elderly NVAF patients received oral anticoagulation, mainly VKAs, while DOACs remained underused. Antiplatelets were still offered to a proportion of patients. Longer duration of NVAF and institutionalization were identified as determinants of VKA use over DOACs. A poor prognosis according to the PROFUND index was identified as a factor preventing the use of oral anticoagulation

    Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.

    No full text
    A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was to characterize the resistance profile of a large cohort of patients failing DAA-based treatments, and investigate the relationship between HCV subtype and failure, as an aid to optimizing management of these patients. A new, standardized HCV-RAS testing protocol based on deep sequencing was designed and applied to 220 previously subtyped samples from patients failing DAA treatment, collected in 39 Spanish hospitals. The majority had received DAA-based interferon (IFN) α-free regimens; 79% had failed sofosbuvir-containing therapy. Genomic regions encoding the nonstructural protein (NS) 3, NS5A, and NS5B (DAA target regions) were analyzed using subtype-specific primers. Viral subtype distribution was as follows: genotype (G) 1, 62.7%; G3a, 21.4%; G4d, 12.3%; G2, 1.8%; and mixed infections 1.8%. Overall, 88.6% of patients carried at least 1 RAS, and 19% carried RAS at frequencies below 20% in the mutant spectrum. There were no differences in RAS selection between treatments with and without ribavirin. Regardless of the treatment received, each HCV subtype showed specific types of RAS. Of note, no RAS were detected in the target proteins of 18.6% of patients failing treatment, and 30.4% of patients had RAS in proteins that were not targets of the inhibitors they received. HCV patients failing DAA therapy showed a high diversity of RAS. Ribavirin use did not influence the type or number of RAS at failure. The subtype-specific pattern of RAS emergence underscores the importance of accurate HCV subtyping. The frequency of "extra-target" RAS suggests the need for RAS screening in all three DAA target regions
    corecore